AstraZeneca Preps for Byetta Lawsuit Litigation over One Diabetes Med While Introducing Another
A medical device manufacturer blamed for injuries in dozens of Byetta lawsuit filings has introduced a new medication for Type 2 diabetics, Medscape Medical News reports.
The March 3rd article indicates that AstraZeneca’s Bydureon Pen has been approved for once-a-week use by the U.S. Food and Drug Administration (FDA) and will become available later in 2014. The pen is prefilled with the same dose of exenatide as in a single-dose tray, but eliminates the need for a patient’s transfer between vial and syringe.
The report states that AstraZeneca’s Bydureon Pen has only been granted approval in the U.S., while the extended-release formulation of the glucagon-like peptide 1 agonist first entered the market in 2012 and is now available in 42 countries worldwide.
In its March report, Medscape references a 24-week study of 252 adult diabetics that found a 1.6 percentage point reduction in hemoglobin levels of patients who used the Bydrureon Pen in comparison to those taking Byetta, whose levels decreased by 0.9 percent. Nausea was also less common in individuals taking the once-weekly injection, research found.
Byetta Pancreatic Cancer Diagnoses Continue to Be Alleged in Lawsuits
AstraZeneca has been named in several lawsuits alleging pancreatic injuries caused by Byetta, according to recent court updates from the U.S. Judicial Panel on Multidistrict Litigation (JPML), who released a report that 306 cases over this medication, as well as Januvia, Victoza and other drugs part of a class known as incretin mimetics, are now pending in a federal litigation established in the Southern District of California. Many of these claims were brought by patients who may have been diagnosed with Byetta pancreatic cancer, pancreatitis, thyroid cancer and other injuries after taking the drug. At the time of the Panel’s previous update on January 15th, a total of 262 cases had been filed in the federal incretin mimetic litigation.
All claims against the makers of Byetta and other Type 2 diabetes medications were filed after a March 2013 announcement from the U.S. Food and Drug Administration (FDA) that noted its launch of a safety review. This investigation was prompted by findings of a previously unpublished study that showed precancerous changes in the pancreas’ of individuals taking Byetta and similar drugs.
File a Byetta Pancreatic Cancer Lawsuit
If you were diagnosed with pancreatic cancer after taking Byetta, you may be eligible to file a lawsuit against its manufacturer. Call the attorneys at Bernstein Liebhard LLP to find out more at (877) 779-1414.